<DOC>
	<DOCNO>NCT00299702</DOCNO>
	<brief_summary>The purpose study compare effectiveness two antipsychotic medication , RisperdalÂ® ConstaÂ® versus AbilifyÂ® , 2-year treatment period long-term maintenance patient schizophrenia .</brief_summary>
	<brief_title>Evaluation Effectiveness Risperdal® Consta® Compared Abilify® Over Two-year Period Patients With Schizophrenia</brief_title>
	<detailed_description>Although many patient schizophrenia currently take oral antipsychotic medication , estimate 75 % difficulty adhere daily oral regimen . Long-acting injectable formulation antipsychotic may eliminate need daily medication enhance patient compliance treatment regimen . The purpose trial evaluate long-term effectiveness Risperdal® Consta® , long-acting injectable antipsychotic medication , versus Abilify® , oral antipsychotic medication patient schizophrenia . The study include patient , investigator 's opinion may benefit change current antipsychotic medication due insufficient effectiveness , side effect difficulty adhere daily dose regimen . This open-label , randomized study patient equal chance receive treatment 2 year Risperdal® Consta® , administer muscle near hip every 2 week , Abilify® , take orally daily . The initial dose subsequent dose study drug determine investigator . The patient 's current oral antipsychotic medication decrease first four week study discontinue . During study , investigator may adjust dose study drug add new antipsychotic medication treat worsen psychotic symptom . Patients may continue add , antidepressant , mood stabilizer ( except carbamazepine ) , sedative hypnotic , anxiolytic medication study . Patients return doctor 's office every two week receive injection Risperdal® Consta® another supply Abilify® . During certain visit , patient ask question help investigator determine severity patient 's illness , well study drug working , quality life , reason , memory , judgement perception side effect may associate schizophrenia treatment . Safety evaluation include incidence adverse event study , vital sign clinical laboratory test ( blood urine ) . The study hypothesis Risperdal® Consta® superior Abilify® long-term treatment subject schizophrenia measure time relapse time remission . Treatment Risperdal® Consta® ( administer muscle every 2 week ) dose 25 , 37.5 50 mg Abilify® ( administer orally daily ) dose 10-30 mg 2 year . Investigators determine start dose may adjust dosage study drug study accord symptom treatment response .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Patients diagnosis schizophrenia Patient least 2 psychotic relapse two year prior study entry patient adequately benefit current antipsychotic medication Patients hospitalize major medication change within 2 month study entry Patients currently experience , experience worsen disease symptom within 2 month study entry Patients currently use clozapine carbamazepine Patients undergone electroconvulsive therapy depot antipsychotic treatment within 6 month prior study entry pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Relapse</keyword>
	<keyword>Remission</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>long-acting injectable</keyword>
</DOC>